CD19-directed Chimeric Antigen Receptor [EPC] - N0000193546
Pharmacologic Class Information
Pharmacologic Code | N0000193546 |
Pharmacologic Name | CD19-directed Chimeric Antigen Receptor |
Pharmacologic Uses |
|
Pharmacologic Concept | Established Pharmacologic Classes - [EPC] |
Pharmacologic Concept Description | An established pharmacologic class is a term or phrase that is scientifically valid
and clinically meaningful according to the following definitions:
|
NDC Products with CD19-directed Chimeric Antigen Receptor
The table contains 3 products whose active ingredient are classified under the same pharmacologic class CD19-directed Chimeric Antigen Receptor [EPC].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0078-0846 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0078-0958 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
71287-119 | Yescarta | Non-Proprietary Name: Axicabtagene Ciloleucel | Suspension | Intravenous | Kite Pharma, Inc. | ACTIVE |